HHS Allows Specialty Pharmacies to Sell Six Unproven Peptides Despite FDA Safety Concerns

Image: Ars Technica · Source

US Health Secretary RFK Jr. has implemented a policy permitting compounding pharmacies to produce and sell six peptides popular in the MAHA movement, overriding FDA objections about their safety and efficacy.

In October 2026, US Health Secretary Robert F. Kennedy Jr. unilaterally introduced an enforcement discretion policy allowing specialty compounding pharmacies to produce and sell six specific peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—despite ongoing FDA warnings about their unproven safety and efficacy. The policy, titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” was published in the Federal Register with a final publication date of October 30, 2026.

These peptides have gained significant popularity within the Make America Health Again (MAHA) movement, with several prominent figures in the group, including Kennedy himself, endorsing and selling them. Kennedy has publicly stated he uses some of these peptides and expressed strong support for them. However, FDA scientists have repeatedly highlighted insufficient clinical evidence to confirm benefits and have flagged potential safety risks. In 2023, these concerns led the FDA to remove the peptides from the list of substances permitted for compounding by specialty pharmacies, aiming to restrict their availability.

The new policy circumvents the FDA’s prior action by stating that the Department of Health and Human Services (HHS) will no longer enforce restrictions against compounding pharmacies producing these peptides. This effectively grants a green light for their manufacture and sale without altering the peptides’ regulatory status.

HHS justified the policy partly based on a July 2026 FDA advisory committee vote to reinstate the peptides on the list for compounding pharmacy production. Notably, Kennedy had appointed eight new members to this 12-person advisory panel before the vote, six of whom have ties to peptide-related industries, raising conflict-of-interest concerns. The rationale also claimed safety issues were largely hypothetical due to limited human studies, suggesting broader availability could reduce risks by keeping usage within controlled compounding pharmacies instead of unregulated black-market sources.

The announcement sparked enthusiasm among peptide sellers online, with some wellness clinic operators and industry advocates thanking Kennedy and political allies for advancing “medical freedom” and patient choice. Conversely, critics expressed serious concerns. The Center for Science in the Public Interest warned that increasing access to unproven peptides could lead to more adverse effects and disincentivize pharmaceutical companies from conducting rigorous trials. Americans for Safe and Effective Medicines highlighted dangers from mass compounding, lack of oversight, and misleading claims, emphasizing the continued FDA warnings regarding lack of data to support safety and effectiveness.

This policy shift illustrates ongoing tensions between regulatory agencies, political leadership, and emerging wellness trends, particularly concerning substances marketed without sufficient scientific validation. The FDA maintains that rigorous evidence is essential to ensure patient safety, while the HHS stance prioritizes patient access and choice despite uncertain benefits. The broader implications for drug regulation and public health remain under close scrutiny.